Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1

Status

Completed 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4Gastrointestinal 1

Conditions

Breast Neoplasms 484Carcinoma, Non-Small-Cell Lung 440Prostatic Neoplasms 292Lung Neoplasms 170Stomach Neoplasms 140Neoplasms 114Squamous Cell Carcinoma of Head and Neck 109Neoplasm Metastasis 97Head and Neck Neoplasms 96Esophageal Neoplasms 71Ovarian Neoplasms 57Pancreatic Neoplasms 42Urinary Bladder Neoplasms 39Sarcoma 39Nasopharyngeal Carcinoma 36Carcinoma, Squamous Cell 30Triple Negative Breast Neoplasms 28Carcinoma, Ovarian Epithelial 28Adenocarcinoma of Lung 27Adenocarcinoma 27Esophageal Squamous Cell Carcinoma 25Parkinson Disease 4, Autosomal Dominant Lewy Body 23Carcinoma, Transitional Cell 23Adenocarcinoma Of Esophagus 23Breast Neoplasms, Male 22Recurrence 21Unspecified Adult Solid Tumor, Protocol Specific 20Inflammatory Breast Neoplasms 20Fallopian Tube Neoplasms 20Melanoma 18

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Observation 3Neoadjuvant Therapy 3Epirubicin 3Endoscopy 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Monatide (IMS 3015) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Pathologic Complete Response × Docetaxel × Clear all
NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Krankenhaus Nordwest

Phase 2/3 Completed
716 enrolled
Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms

NCT00636441 2015-12-11

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Duke University

Phase 2 Terminated
56 enrolled 16 charts
Breast

Pathologic Complete Response, Breast Neoplasms

NCT02613026 2015-11-24

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

307 Hospital of PLA

Phase 3 Completed
104 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡